abiraterone has been researched along with Lassitude in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bisbjerg, R; Fode, M; Kistorp, CM; Kvorning Ternov, K; Lindberg, H; Palapattu, G; Sønksen, J; Østergren, PB | 1 |
| Bianchini, D; Cheng, T; Chi, KN; Chieffo, N; Chu, L; de Bono, JS; Efstathiou, E; Ellard, SL; Fizazi, K; Flaig, TW; Fléchon, A; Goodman, OB; Hainsworth, JD; Haqq, CM; Harland, S; Hutson, TE; Jones, RJ; Kheoh, T; Logothetis, CJ; Loriot, Y; Mainwaring, P; Molina, A; North, S; Patterson, H; Ryan, CJ; Saad, F; Saleh, M; Scher, HI; Scholz, M; Staffurth, JN; Sternberg, CN; Zivi, A | 1 |
| Chieffo, N; Efstathiou, E; Hoang, A; Karlou, M; Logothetis, CJ; Molina, A; Smith, LA; Titus, M; Troncoso, P; Tsavachidou, D; Tzelepi, V; Wen, S | 1 |
3 trial(s) available for abiraterone and Lassitude
| Article | Year |
|---|---|
Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Glucose; Clinical Trials, Phase III as Topic; Denmark; Fatigue; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Fatigue; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Survival Analysis; Treatment Outcome | 2011 |
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Bone Marrow; Bone Neoplasms; Castration; Disease-Free Survival; Drug Administration Schedule; Fatigue; Histone Deacetylase Inhibitors; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Nausea; Prostatic Neoplasms; Receptors, Androgen; Remission Induction; Testosterone; Vascular Diseases; Young Adult | 2012 |